SNHG14 lncRNA as a Prognostic Biomarker in Adult Non-M3 AML Patients.

BACKGROUND AND

OBJECTIVES

Acute myeloid leukemia (AML) is one of the most common blood malignancies in adults, characterized by the involvement of hematopoietic myeloid progenitors. Numerous studies have demonstrated the involvement of long noncoding RNAs (lncRNAs) in AML pathogenesis. This study aimed to investigate the expression profile of lncRNA small nuclear RNA host gene 14 (SNHG14) and its role in the pathogenesis, clinical features, and prognosis of adult non-M3 AML.

MATERIALS AND

METHODS

The expression level of SNHG14 was evaluated in bone marrow (BM) samples obtained from 50 adult non-M3 AML patients and 49 healthy controls using Quantitative Reverse Transcription-Polymerase Chain Reaction. We also investigated the correlation between clinicopathological characteristics and SNHG14 expression levels in AML patients.

RESULTS

The expression level of SNHG14 was significantly decreased in the BM tissues of adult non-M3 AML patients compared to healthy controls. Patients with low SNHG14 expression were associated with poor overall survival, while no correlation was found between low SNHG14 expression and relapse-free survival.

CONCLUSION

Our findings suggest that SNHG14 expression could serve as a potential biomarker for prognosing adult non-M3 AML patients. Furthermore, SNHG14 may offer insights into novel therapeutic targets for this subset of AML patients.